Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
A growing amount of evidence indicates that matrix metalloproteinases (MMPs) may play an important role in the pathogenesis of Alzheimer's disease (AD). Stromelysin-1 (MMP-3) plays a central role in activating latent-type MMPs, which are originally secreted as proenzymes. We examined MMP-3 immunoreactivity in the brains of patients who had suffered from Alzheimer's disease and in those of neurologically normal persons. The interstitium between myelinated axons and astrocytes in the white matter of all brain tissues, and senile plaques in the gray matter of the patients with AD were stained with a monoclonal antibody to MMP-3. Comparison of the number of senile plaques stained with the antibody against MMP-3 in the parietal cortex with that in the hippocampus showed that fewer plaques were stained in the hippocampus. The selective distribution of MMP-3 in the human brain suggests that MMP-3 might play an important role in the pathogenesis of AD, especially in the degradation of beta-amyloid protein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Enhanced expression of MMP-2 and MMP-9 has been found in astrocytes surrounding amyloid plaques and in the neurons and glia of the hippocampus after intracerebroventricular Ab injection (25)(26)(27)(28).”
From Differential protective effects of connective tissue growth factor against Aβ neurotoxicity on neurons and glia (2017) · cites this paper as [27]
In the citing paper
“while increased levels of metaloproteinases MMP-1, MMP-3 and MMP-10 have also been reported in AD [223,224,225,226].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [226]
Citations
Cites
Alzheimer's Disease: A Central Role for Amyloid
Selkoe, D. J. (1994) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199409000-00003 · Cited by 751
Multiple domains of the large fibroblast proteoglycan, versican.
Zimmermann, D. R., & Ruoslahti, E. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08447.x · Cited by 652
A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor
Miyazaki, K., Hasegawa, M., Funahashi, K., & Umeda, M. (1993) · Nature · doi:10.1038/362839a0 · Cited by 175
Su, J. H., Cummings, B. J., & Cotman, C. W. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90521-3 · Cited by 173
Deb, S., & Gottschall, P. E. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66041641.x · Cited by 163
Snow, A. D., Mar, H., Nochlin, D., Kresse, H., & Wight, T. N. (1992) · Journal of Histochemistry & Cytochemistry · doi:10.1177/40.1.1370306 · Cited by 144
Backstrom, J. R., Miller, C. A., & Tökés, Z. A. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09352.x · Cited by 109
Roughley, P. J., White, R. J., & Poole, A. R. (1985) · Biochemical Journal · doi:10.1042/bj2310129 · Cited by 93
Yamada, T., Yoshiyama, Y., Sato, H., Seiki, M., Shinagawa, A., & Takahashi, M. (1995) · Acta Neuropathologica · doi:10.1007/bf00294800 · Cited by 85
Self-citationIsolation of a large aggregating proteoglycan from human brain.
Perides, G., Rahemtulla, F., Lane, W. S., Asher, R. A., & Bignami, A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35919-2 · Cited by 73
Cited by
Physiology and pathophysiology of matrix metalloproteases
Klein, T., & Bischoff, R. (2011) · Amino Acids · doi:10.1007/s00726-010-0689-x · Cited by 828
“2003), Alzheimer’s disease (Yoshiyama et al. 2000) and various cancers (Mercapide et al.”
BackgroundMatrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Galtrey, C. M., & Fawcett, J. W. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.09.006 · Cited by 575
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381
“Both MMPs are expressed in cultured rat astrocytes, and MMP-3 expression is increased in AD brains and in astrocytes treated with A (Deb and Gottschall, 1996; Yoshiyama et al., 2000).”
BackgroundAmyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331
“Enzyme Name Substrate Levels/Activity in AD Brain vs. Control Metal - Binding References Neprilysin Aβ, Bradykinin, Substance P, Angiotensin-I, Angiotensin-II, Endothelin-1, Kinins, Adrenomedullin, Opioid peptides, enkephalin, gastrin Increased Reduced Zinc [150, 149] Endothelin-converting enzymes (ECE) Aβ, Endothelin…”
BackgroundInfluentialCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
“AD brains also present increased levels of other SASPs mediators: the metalloproteinases MMP1, MMP-3, and MMP-10 (Leake et al., 2000; Yoshiyama et al., 2000; Bjerke et al., 2011; Horstmann et al., 2018).”
BackgroundDeciphering the astrocyte reaction in Alzheimer's disease
Perez-Nievas, B. G., & Serrano-Pozo, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00114 · Cited by 282
“MMP3 is present in plaques and in white matter fibrous astrocytes in the AD brain (Yoshiyama et al., 2000; but see also, Baig et al., 2008).”
BackgroundMeighan, S. E., Meighan, P. C., Choudhury, P., Davis, C. J., Olson, M. L., Zornes, P. A., Wright, J. W., & Harding, J. W. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03565.x · Cited by 285
“…(Anthony et al. 1998), whereas increased latent hippocampal MMP-9 and decreased MMP-3 in patients with Alzheimer’s disease has led to speculation that a decrease in active MMP-9 could be involved in the deposition of b-amyloid (Deb and Gottschall 1996; Lim et al. 1997; Yoshiyama et al. 2000).”
BackgroundOxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
“Potential roles of MMPs in Ab deposition in the brain promotes influx of circulating Ab across the BBB (Saarela et al. 2004; Yoshiyama et al. 2000) Neuromol Med (2011) 13:223–250 231”
BackgroundTargeting the neural extracellular matrix in neurological disorders
Soleman, S., Filippov, M. A., Dityatev, A., & Fawcett, J. W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.050 · Cited by 244
“MMP-2, MMP-3 and MMP-9 are overexpressed in AD brain (Backstrom et al., 1996; Yoshiyama et al., 2000; Asahina et al., 2001; Bruno et al., 2009) and as well as in neuronal cultures and astrocytes (Deb and Gottschall, 1996; Yoshiyama et al.”
BackgroundProteolytic Cleavage of Extracellular Secreted α-Synuclein via Matrix Metalloproteinases
Sung, J. Y., Park, S. M., Lee, C.-H., Um, J. W., Lee, H. J., Kim, J., Oh, Y. J., Lee, S.-T., Paik, S. R., & Chung, K. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503341200 · Cited by 238
Behl, T., Kaur, G., Sehgal, A., Bhardwaj, S., Singh, S., Buhas, C., Judea-Pusta, C., Uivarosan, D., Munteanu, M. A., & Bungau, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031413 · Cited by 186
Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180
“It has been shown that the expression of MMP−3 and MMP−9 are elevated in the human brain and co-localize with amyloid plaques and neurofibrillary tangles [65, 66].”
Walker, D. G., Link, J., Lue, L.-F., Dalsing-Hernandez, J. E., & Boyes, B. E. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705377 · Cited by 180
Amyloid β Oligomers Disrupt Blood–CSF Barrier Integrity by Activating Matrix Metalloproteinases
Brkic, M., Balusu, S., Van Wonterghem, E., Gorlé, N., Benilova, I., Kremer, A., Van Hove, I., Moons, L., De Strooper, B., Kanazir, S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0006-15.2015 · Cited by 182
“Interestingly, several recent studies propose MMP3 as a potential biomarker for Alzheimer’s disease because it is significantly upregulated in the brain, CSF, and plasma of Alzheimer’s disease patients (Yoshiyama et al., 2000; Horstmann et al., 2010; Hanzel et al., 2014; Kauwe et al., 2014; Mroczko et al., 2014).”
BackgroundClinical implications of matrix metalloproteinases
Mandal, M., Mandal, A., Das, S., Chakraborti, T., & Chakraborti, S. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1025526424637 · Cited by 171
“The selective distribution of MMP-3 in the human brain suggests that MMP-3 might play an important role in the pathogenesis of AD, especially in the degradation of βamyloid protein [201].”
BackgroundWright, J. W., & Harding, J. W. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.03.003 · Cited by 169
Lorenzl, S., Albers, D. S., Narr, S., Chirichigno, J. W., & Beal, M. F. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8019 · Cited by 167
Brelstaff, J. H., Mason, M., Katsinelos, T., McEwan, W. A., Ghetti, B., Tolkovsky, A. M., & Spillantini, M. G. (2021) · Science Advances · doi:10.1126/sciadv.abg4980 · Cited by 135
“Nevertheless, activation of MMP3 is a hallmark of several tauopathies, including AD and familial FTD cases (69-71).”
Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome
Iulita, M. F., & Cuello, A. C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.010 · Cited by 149
Kauwe, J. S. K., Bailey, M. H., Ridge, P. G., Perry, R., Wadsworth, M. E., Hoyt, K. L., Staley, L. A., Karch, C. M., Harari, O., Cruchaga, C., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004758 · Cited by 125
“MMP9 can degrade fibrillar Ab in vitro and plaques in hippocampal slice cultures [52,56,57].”
Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease
Madav, Y., Wairkar, S., & Prabhakar, B. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.01.004 · Cited by 111
Role of matrix metalloproteinase-3 in neurodegeneration: Role of MMP-3 in neurodegeneration
Kim, E.-M., & Hwang, O. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07082.x · Cited by 115
“has been detected around senile plaques in the gray matter and in the interstitium between myelinated axons and astrocytes of white matter of AD patients (Yoshiyama et al. 2000).”
BackgroundMatrix metalloproteinase‐3 in the central nervous system: a look on the bright side
Van Hove, I., Lemmens, K., Van de Velde, S., Verslegers, M., & Moons, L. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07900.x · Cited by 112
“In the healthy elderly human brain (age range from 71 to 93 years), diverse studies showed perineuronal, neuronal and neuropil MMP-3 labelling in the frontal cortex, but MMP-3 was not found in the parietal cortex or hippocampus (Yoshiyama et al. 2000; Baig et al. 2008).”
Rivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
“Also in post mortem brain tissue, MT5MMP immunostaining was detected in amyloid plaques [90] and MT1-MMP in microglial cells neighbouring plaques [84], while MMP-3 was found in both amyloid plaques and the interstitium between myelinated axons and astrocytes, in particular, in the parietal cortex [91].”
BackgroundHorstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C., & Wagner, S. (2010) · International Psychogeriatrics · doi:10.1017/s1041610210000827 · Cited by 110
“It plays an important role in activating MMP-9, which is involved in amyloid β degradation (Yoshiyama et al., 2000) as well as being directly involved in amyloid β degradation itself (White et al., 2006).”
BackgroundResultInfluentialProteolysis of AA Amyloid Fibril Proteins by Matrix Metalloproteinases-1, -2, and -3
Stix, B., Kähne, T., Sletten, K., Raynes, J. G., Roessner, A., & Röcken, C. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61727-0 · Cited by 111
Stomrud, E., Björkqvist, M., Janciauskiene, S., Minthon, L., & Hansson, O. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt44 · Cited by 103
“The findings of this study are in alignment with the elevated expression of MMP-3 and MMP-9 that have been observed in brain tissue of patients with established AD [7,8].”
BackgroundResultMatrix Metalloproteinases, New Insights into the Understanding of Neurodegenerative Disorders
Kim, Y.-S., & Joh, T.-H. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.2.133 · Cited by 104
“Double immunostaining of MMP-3 and GFAP in the white matter suggests that astrocytes may be a major source of MMP-3 in AD brain (Yoshiyama et al., 2000).”
BackgroundIulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
“MMP-3 elevations occur in brains [92] and CSF [85,87] of Alzheimer patients.”
BackgroundGoicovich, E., Molina, C., Pérez, P., Aguilera, S., Fernández, J., Olea, N., Alliende, C., Leyton, C., Romo, R., Leyton, L., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11178 · Cited by 96
Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94
Katz, D. H., Tahir, U. A., Bick, A. G., Pampana, A., Ngo, D., Benson, M. D., Yu, Z., Robbins, J. M., Chen, Z.-Z., Cruz, D. E., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055117 · Cited by 92
β-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes
Deb, S., Wenjun Zhang, J., & Gottschall, P. E. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02344-8 · Cited by 81
Ito, S., Kimura, K., Haneda, M., Ishida, Y., Sawada, M., & Isobe, K. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.11.012 · Cited by 90
Baillat, D., Bègue, A., Stéhelin, D., & Aumercier, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200088200 · Cited by 84
ECM in brain aging and dementia
Morawski, M., Filippov, M., Tzinia, A., Tsilibary, E., & Vargova, L. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63486-3.00010-4 · Cited by 84
“Additionally, the MMP-3 protein level is elevated in the brains of AD, and MMP-3 has been detected around senile plaques of AD patients (Yoshiyama et al., 2000).”
Matrix metalloproteinases and cellular motility in development and disease
VanSaun, M. N., & Matrisian, L. M. (2006) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20061 · Cited by 93
Neural plasticity and the brain renin–angiotensin system
Wright, J. W., Reichert, J. R., Davis, C. J., & Harding, J. W. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00019-2 · Cited by 87
Wright, J. W., Kramár, E. A., Meighan, S. E., & Harding, J. W. (2002) · Peptides · doi:10.1016/s0196-9781(01)00599-x · Cited by 86
Wright, J. W., & Harding, J. W. (2009) · Neural Plasticity · doi:10.1155/2009/579382 · Cited by 80
Cell senescence in neuropathology: A focus on neurodegeneration and tumours
Carreno, G., Guiho, R., & Martinez‐Barbera, J. P. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12689 · Cited by 74
Thirumangalakudi, L., Yin, L., Rao, H. V., & Grammas, P. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11307 · Cited by 73
“MMPs are demonstrable in the AD brain and are localized to areas of neuropathology[44].”
Viejo, L., Noori, A., Merrill, E., Das, S., Hyman, B. T., & Serrano‐Pozo, A. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12753 · Cited by 69
“Extracellular matrix Reactive astrocytes in AD also play an essential role in reorganisation of the extracellular matrix, as judged by their increased immunoreactivity for secreted proteases such as the matrix metalloproteinases interstitial collagenase (MMP1) [112] and stromelysin-1 (MMP3) [113] as well as urokinase-…”
BackgroundInfluentialLorenzl, S., Calingasan, N. Y., Yang, L., Albers, D. S., Shugama, S., Gregorio, J., Krell, H. W., Chirichigno, J. W., JOH, T. H., & Beal, M. F. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:2:119 · Cited by 69
“…al., 1993; Maeda and Sobel, 1996) and neurodegenerative diseases such as Alzheimer’s disease (Asahina et al., 2001; Leake et al., 2000; Lorenzl et al., 2003; Miyazaki et al., 1993; Peres et al., 1995; Yoshiyama et al., 2000) and amyotrophic lateral sclerosis (Beuche et al., 2000; Lim et al., 1996).”
BackgroundHanzel, C. E., Iulita, M. F., Eyjolfsdottir, H., Hjorth, E., Schultzberg, M., Eriksdotter, M., & Cuello, A. C. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132282 · Cited by 64
“It is significantly increased in AD brains and in plasma, compared to control subjects, localizing in close proximity to amyloid plaques [11, 12].”
BackgroundMroczko, B., Groblewska, M., & Barcikowska, M. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130647 · Cited by 61
“Furthermore, overexpression of MMP-3 in astrocytes and neurons exposed to A 1-40 was demonstrated [35].”
InfluentialKorotkov, A., Broekaart, D. W. M., van Scheppingen, J., Anink, J. J., Baayen, J. C., Idema, S., Gorter, J. A., Aronica, E., & van Vliet, E. A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1245-y · Cited by 60
Nübling, G., Levin, J., Bader, B., Israel, L., Bötzel, K., Lorenzl, S., & Giese, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.07.018 · Cited by 66
“AD, MMP-3 was co-localized with senile plaques, with overall lower levels in the hippocampal area (Yoshiyama et al., 2000).”
BackgroundInfluentialMroczko, B., Groblewska, M., Zboch, M., Kulczyńska, A., Koper, O. M., Szmitkowski, M., Kornhuber, J., & Lewczuk, P. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131634 · Cited by 57
“briefly summarized in the Table 2 [11, 13, 15, 23–29].”
Influence of hippocampectomy on habituation, exploratory behavior, and spatial memory in rats
Wright, J. W., Murphy, E. S., Elijah, I. E., Holtfreter, K. L., Davis, C. J., Olson, M. L., Muhunthan, K., & Harding, J. W. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.083 · Cited by 61
Yoshiyama, Y., Kojima, A., Itoh, K., Uchiyama, T., & Arai, K. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.017 · Cited by 54
Self-citationMatrix metalloproteinase profiling and their roles in disease
Chang, M. (2023) · RSC Advances · doi:10.1039/d2ra07005g · Cited by 54
The Link Between Matrix Metalloproteinases and Alzheimer’s Disease Pathophysiology
Radošinská, D., & Radošinská, J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04315-0 · Cited by 55
“Comparison of MMP-3-posi-tive amyloid plaques showed a higher density in the parietal cortex than in the hippocampus [55].”
Winterhalter, C., Widera, P., & Krasnogor, N. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt732 · Cited by 48
“However, the proteins from the matrix metalloproteinase MMP17 family are capable of degrading the β -amyloid proteins and it is speculated that distribution of MMPs in the brain matter is a part of Alzheimer’s pathomechanism (Yoshiyama et al. , 2000).”
BackgroundBehl, T., Kaur, I., Fratila, O., Brata, R., & Bungau, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207443 · Cited by 42
“Neprilysin (NEP) Aβ load-reducing enzyme [2] Endothelin-converting enzyme (ECE) Aβ load-reducing enzyme [85] Protein kinase C epsilon (PKCε) ECE enhancer, Aβ load reducer [86] Serine protease plasmin Amyloid degradation [88] Matrix metalloproteinases (MMPs) Amyloid degradation [89–91] Estrogen MMP-2, -9 enhancer, Aβ c…”
BackgroundInfluentialIulita, M. F., Ganesh, A., Pentz, R., Flores Aguilar, L., Gubert, P., Ducatenzeiler, A., Christie, S., Wilcock, G. K., & Cuello, A. C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180970 · Cited by 43
“In the brain, MMP-3 derived from neurons under metabolic stress is reported to participate in microglia activation and in the induction of neuroinflammation [49, 50].”
Mizuno, H., Warita, H., Aoki, M., & Itoyama, Y. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21702 · Cited by 52
“MMPs are rapidly up-regulated after almost all types of CNS insult, including spinal cord injury (de Castro et al., 2000), ischemia (Rosenberg, 1995; Muir et al., 2002), and Alzheimer’s disease (Yoshiyama et al., 2000).”
BackgroundRohn, T. T., Catlin, L. W., Coonse, K., & Habig, J. W. (2012) · Brain Research · doi:10.1016/j.brainres.2012.08.003 · Cited by 46
“For example, MMP-3 has a selective distribution in the AD brain being found in astrocytes and within senile plaques (Yoshiyama et al., 2000).”
Stefano, M. E. D., & Herrero, M. T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.08.002 · Cited by 43
“…induces an increase in MMP-2 and MMP-9 secretion by astrocytes and microglia, and then promotes microgliosis- and astrogliosis-based neuroinflammation, with over-production of pro-inflammatory MMPs, including MMP-3 (Yoshiyama et al., 2000; Yan et al., 2006; Walsh et al., 2007; Kim and Hwang, 2011).”
Ajmo, J. M., Bailey, L. A., Howell, M. D., Cortez, L. K., Pennypacker, K. R., Mehta, H. N., Morgan, D., Gordon, M. N., & Gottschall, P. E. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06647.x · Cited by 41
“Although expression is relatively low in unperturbed brain tissue, MMP protein levels have been shown to be increased in AD brain (Backstrom et al. 1996; Leake et al. 2000; Yoshiyama et al. 2000; Asahina et al. 2001) and these proteases were capable of degrading ECM and Ab (Backstrom et al.”
MMP3 at the crossroads: Linking molecular pathways to disease diagnosis and therapy
Jiang, J., Wu, Q., Rajasekaran, S., & Wu, R. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107750 · Cited by 46
MMP‐3 mediates psychosine‐induced globoid cell formation: Implications for leukodystrophy pathology
Ijichi, K., Brown, G. D., Moore, C. S., Lee, J., Winokur, P. N., Pagarigan, R. R., Snyder, E. Y., Bongarzone, E. R., & Crocker, S. J. (2013) · Glia · doi:10.1002/glia.22471 · Cited by 45
Baig, S., Kehoe, P. G., & Love, S. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00897.x · Cited by 38
Expression of invariant chain and pro-cathepsin L in Alzheimer's brain
Yoshiyama, Y., Arai, K., Oki, T., & Hattori, T. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01326-4 · Cited by 37
Self-citationThe Role of Vitamin D in Alzheimer’s Disease: Possible Genetic and Cell Signaling Mechanisms
Lương, K. V. Q., & Nguyễn, L. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512473196 · Cited by 42
“The MMP-3 was expressed predominantly in white matter of brain and was also expressed in senile plaques in the cortices of patients with AD.(137) The MMP-9 levels were significantly elevated in the plasma of patients with AD compared to the controls.”
BackgroundMüller, D., Roessner, A., & Röcken, C. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000271 · Cited by 35
“SAA [17], MMPs within amyloid deposits may be involved in the proteolysis of the precursor and/or fibril proteins of AA amyloid instead of tissue remodeling, as was speculated for Aβ amyloidosis associated with Alzheimer’s disease [ 32 ].”
BackgroundMatrix Metalloproteinase-9 Regulates Survival of Neurons in Newborn Hippocampus
Murase, S., & McKay, R. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.297671 · Cited by 33
“Genes for MMPs are associated with neurodegenerative diseases (36), and up-regulation of MMPs is reported in patients with Alzheimer disease (37, 38) and in animal models of Parkinson disease (39, 40).”
BackgroundMetalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Gargiulo, S., Gamba, P., Poli, G., & Leonarduzzi, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660701 · Cited by 35
“MMP-3, for example, has been detected around senile plaques, in the grey matter and in the interstitium between myelinated axons and astrocytes in the white matter of AD patients [387].”
BackgroundLương, K. V. Q., & Nguyễn, L. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513488924 · Cited by 35
“matter and was also expressed in senile plaques in the cortices of patients with AD.(136) Compared with the control participants, patients with AD had significantly elevated plasma MMP-9 levels.”
Pentz, R., Iulita, M. F., Mikutra-Cencora, M., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105150 · Cited by 31
WRIGHT, J., Meighan, S. E., MURPHY, E., Holtfreter, K. L., Davis, C. J., OLSON, M., Benoist, C. C., Muhunthan, K., & Harding, J. W. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.07.006 · Cited by 32
Shibata, N., Ohnuma, T., Higashi, S., Usui, C., Ohkubo, T., Kitajima, A., Ueki, A., Nagao, M., & Arai, H. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.09.004 · Cited by 29
Implication of matrix metalloproteinases in regulating neuronal disorder
Mukherjee, A. K., & Swarnakar, S. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3752-y · Cited by 28
“The increase in MMP-3 and -9 expressions have been observed in the hippocampus of AD patients [66, 67].”
BackgroundYang, C.-N., Wu, M.-F., Liu, C.-C., Jung, W.-H., Chang, Y.-C., Lee, W.-P., Shiao, Y.-J., Wu, C.-L., Liou, H.-H., Lin, S.-K., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx278 · Cited by 27
Endothelins stimulate the production of stromelysin-1 in cultured rat astrocytes
Kōyama, Y., & Tanaka, K. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.064 · Cited by 27
Lorenzl, S., Albers, D. S., Chirichigno, J. W., Augood, S. J., & Beal, M. F. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.10.015 · Cited by 29
Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases
Khotimchenko, Y. S., Silachev, D. N., & Katanaev, V. L. (2022) · Marine Drugs · doi:10.3390/md20110708 · Cited by 27
Wang, Z., Tang, X., Swaminathan, S. K., Kandimalla, K. K., & Kalari, K. R. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-022-00235-8 · Cited by 25
Saarela, M., Lehtimäki, T. J., Rinne, J. O., Hervonen, A., Jylhä, M. K., Röyttä, M., Ahonen, J.-P., & Mattila, K. M. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.027 · Cited by 23
Impact of the matrix metalloproteinase MMP-3 on dementia
Helbecque, N., Cottel, D., Hermant, X., & Amouyel, P. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.030 · Cited by 24
Matrix metalloproteinase-3 in brain physiology and neurodegeneration
Lech, A. M., Wiera, G., & Mozrzymas, J. W. (2019) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/110319 · Cited by 24
Metalloproteinases and neurodegenerative diseases: pathophysiological and therapeutic perspectives
Rosenberg, G. A. (2015) · Metalloproteinases In Medicine · doi:10.2147/mnm.s68849 · Cited by 27
“Immunohistochemistry has also detected MMP-3 expression in hippocampal neurons, around amyloid plaques in the cortex.(76) Hypertension (SHR/SP)”
BackgroundBrzdak, P., Nowak, D., Wiera, G., & Mozrzymas, J. W. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00178 · Cited by 21
“MMP-9 was detected in the cytoplasm of neurons and co-localized with neurofibrillary tangles and Aβ plaques (Yoshiyama et al., 2000; Yin et al., 2006; Mizoguchi et al., 2011b).”
BackgroundMatrix metalloproteinase-3 induction in rat brain astrocytes: focus on the role of two AP-1 elements
Kim, K. S., Kim, H. Y., Joe, E.-H., & Jou, I. (2008) · Biochemical Journal · doi:10.1042/bj20071207 · Cited by 21
Sex-specific associations of matrix metalloproteinases in Alzheimer’s disease
Aksnes, M., Edwin, T. H., Saltvedt, I. T., Eldholm, R. S., Chaudhry, F. A., Halaas, N. B., Myrstad, M., Watne, L. O., & Knapskog, A. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00514-x · Cited by 21
Wang, P., Anderson, D. E., & Ye, Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01128-x · Cited by 20
“Additionally, in AD brain, Mmp3 expression is high in astrocytes around neurofibrillary tangles and amyloid plaques [48].”
BackgroundMaroto, M., Fernández‐Morales, J., Padín, J. F., Gonzalez, J., Hernández-Guijo, J. M., Montell, E., Vergés, J., de Diego, A. M. G., & de Diego, A. M. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12159 · Cited by 22
“Matrix metalloproteases also are rapidly up-regulated after nearly all types of CNS insult, including spinal cord injury (Xu et al. 2001), Alzheimer′s disease (Yoshiyama et al. 2000), and stroke (Sole et al. 2004).”
BackgroundMarine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation
Gentile, E., & Liuzzi, G. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.023 · Cited by 19
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 20
“…was reported to be increased (Asahina et al., 2001; Backstrom et al., 1996; Kikuchi et al., 2021; Langenfurth et al., 2014; Terni & Ferrer, 2015; Yoshiyama et al., 2000), although one study found no differences for MMP- 2, MMP- 3, and MMP- 9 concentrations or activity between AD and control…”
BackgroundMatrix Metalloproteinases in Cerebral Ischemia
Kim, H. Y., & Han, S. (2006) · Journal of Clinical Neurology · doi:10.3988/jcn.2006.2.3.163 · Cited by 21
Xia, M., Su, Y., Fu, J., Xu, J., Wang, Q., Gao, F., Shen, Y., Dong, Q., & Cheng, X. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210288 · Cited by 16
“Inthe brain,MMP-3canbederivedfromneuronsunder stress, which participates in microglia activation and neuroinflammation [30, 31].”
Ďurmanová, V., Javor, J., Párnická, Z., Minárik, G., Ocenasova, A., Vašečková, B., Režnáková, V., Kralova, M., Hromádka, T., & Shawkatová, I. (2021) · Mediators of Inflammation · doi:10.1155/2021/5573642 · Cited by 18
“In AD patients, an increase in MMP-2 and MMP-3 expression in the astrocytes surrounding amyloid plaques was reported [26, 48].”
Microglia: Roles of Microglia in Chronic Neurodegenerative Diseases
Wood, P. L. (2003) · Humana Press eBooks · doi:10.1385/1-59259-297-x:003 · Cited by 14
Current Naturopathy to Combat Alzheimer’s Disease
Chakrovorty, A., Bhattacharjee, B., Saxena, A., Samadder, A., & Nandi, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220927121022 · Cited by 14
“An in-silico study performed by Kumar et al. validated 17 phytochemicals isolated from Withania somnif-era to bind with high affinity to the S1'-specificity pocket of the MMP-9 catalytic domain and lead to its functional inhibition [67-70].”
MethodMatrix metalloproteinase–19 expressed in cerebral amyloid angiopathy
Tanskanen, M., Myllykangas, L., Saarialho‐Kere, U., & Paetau, A. E. (2011) · Amyloid · doi:10.3109/13506129.2010.541960 · Cited by 14
“In the brain, MMPs are able to degrade Ab [11] and fibrillar amyloid in AD as well [12].”
BackgroundPehlivan, S., Fedakar, R., Eren, B., Akyol, S., Eren, F., İnanır, N. T., Gürses, M. S., Ural, M., Tağıl, S. M., & Demircan, K. (2016) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20150706034008 · Cited by 12
“Biochem Biophys Res Commun 2005;328(2):608-17.”
Hu, T., You, Q., Chen, D., Tong, J., Shang, L., Luo, J., Qiu, Y., Yu, H., Zeng, L., & Huang, J. (2016) · Neurochemical Research · doi:10.1007/s11064-015-1800-1 · Cited by 11
“MMP-3 labelling was existed in perineuron, neuron and neuropil in the frontal cortex [28, 29] and perivascular microglia [30].”
Background
Metadata
- Authors
- Yoshiyama, Y., Asahina, M., & Hattori, T.
- Affiliations
- Chiba University (JP)
- Venue
- Acta Neuropathologica
- Published
- 2000-01-05
- Volume
- 99
- Issue
- 2
- Pages
- 91-95
- ISSN
- 0001-6322 (ISSN-L)
- OpenAlex
- W2033779398
- Cited by
- 128
- References
- 11
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 1 · 2023: 8 · 2022: 3 · 2021: 10 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 7 · 2015: 3 · 2014: 8 · 2013: 8 · 2012: 5
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- matrix metalloproteinase-3, stromelysin-1, Alzheimer's disease, amyloid plaques, white matter, hippocampus, parietal cortex, MMP activation
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Antibodies, Monoclonal, Astrocytes, Axons, Brain, Female, Hippocampus, Humans, Immunohistochemistry, Male, Middle Aged, Parietal Lobe, Reference Values, Matrix Metalloproteinase 3, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.